logo
  • SELECT LICENSE :

  • US $4,299.00
  • US $8,599.00

Lung Cancer Market, By Type (SCLC, NSCLC), By Treatment (Surgery, Radiotherapy, Chemotherapy, Laser Therapy, Photodynamic Therapy) By Application (Hospitals and Clinics, Cancer Research Centre, Laboratories) opportunities and forecast 2020-2027

  • DLR2172
  • 19 September, 2020
  • Pharma & Healthcare
  • Pages: 120
  • Global
Market Overview

Lung cancer, second most common type of the cancer in both women and men, with almost 13% of all new cancers anticipated to be the cases of lung cancer. According to American Cancer Society (ACS), the rate of lung cancer is high in the U.S., resulting in the deaths of over 142,000 people in 2019. The market has been driven by growing cancer research and rapid growth in the occurrence of lung cancer, which has led government to fund the cancer research. The rising government support to the lung cancer research, and rising private investment in the industry, is likely to be the major driver for the global lung cancer market during the forecast period.

In Feb 2019, the technology that could power the new biosensor was presented by the researchers at University of Exeter. This biosensor were expected to help detect the lung cancer at an earlier stage, considerably improving the chances of survival. The biosensor is created on graphene and has the capacity to sense small molecules of the common lung cancer biomarkers, permitting it to detect the existence of cancerous tumours at lower concentration of the biomarkers, thus at an quite earlier stage of the disease. Developing and improving technology allowing early-stage analysis is likely to be a successful avenue for major players in the market during the forecast period.

Segment Overview

Based on type the global lung cancer market has been segmented as small cell lung cancer and non-small cell lung cancer. NSCLC more common than the small cell lung cancer and are expected to have higher prevalence figures. On the basis of treatment, the market is segmented into surgery, chemotherapy, photodynamic therapy (PDT), radiotherapy, and laser therapy. By end use, the market comprises cancer research centres, hospitals & clinics, and laboratories.

Regional Overview

The global lung cancer market is segmented as North America, Europe, Asia Pacific, and the Latin America and Middle East and Africa (LAMEA) on the basis of region.
North America is expected to remain the key regional player in the global market over the forecast period owing to the presence of advanced healthcare sector and high disposable income of the consumers in the region.

On the other hand, Europe commanded the second largest share in the global market. The two regional segments are expected to remain the foremost players in the global market, as the lung cancer study facilities in the regions are of highest standards and home to a teeming research environment.

Competitor overview

The market is consolidated and almost all the major players are operating in the market. Hence the market is highly competitive and players are investing on new and enhanced product development to treat the diseases.
For instance; in 2016, Novartis AG's drug for cancer got FDA’s principal bio similar confirmation. Federal regulators permitted the first of the bio similar drug to be sold in the U.S. under a platform intended to branch new market of lower-cost alternatives to some of the expensive treatments in healthcare. The approval of biosimilars is expected to help many patients who need such treatments.
Moreover, in August 2016, FDA approved Pfizer’s TROXYCA ER extended-release capsules CII for the pain management. The drug was used for abuse-deterrent properties for management of pain and helped the company to improve its sales and goodwill with this new product. In Feb 2015, F. Hoffmann-La Roche Ltd attained Signature Diagnostics AG (Signature), a privately held drug manufacturing company based in Potsdam, Germany.

Key Players
  1. F. Hoffman-La Roche
  2. Pfizer Inc.
  3. Bristol-Myers Squibb Company
  4. Sanofi
  5. Eli Lilly and Company
  6. Merck & Co. Inc.
  7. Novartis.
  8. Bayer AG
  9. Daiichi Sankyo Co., Ltd.

Market Segmentation

By Type
  • Small Cell Lung Cancer (SCLC)
  • Non-Small Cell Lung Cancer (NSCLC)
By Treatment
  • Surgery
  • Chemotherapy
  • Radiotherapy
  • Laser Therapy
  • Photodynamic Therapy
By Application
  • Hospitals and Clinics
  • Cancer Research Centre
  • Laboratories
By Geography
  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • UAE
    • Rest of LAMEA


1 Report Prologue 11

    2 Introduction 15

    • 2.1 Pipeline Development 15
    • 2.2 Research Objective 21
    • 2.3 Assumptions & Limitations 22
      • 2.3.1 Assumptions 22
      • 2.3.2 Limitations 22
    • 2.4 Market Structure 22

    3 Research Methodology 23

    • 3.1 Primary Research 24
    • 3.2 Secondary Research 24

    4 Porter’s Five Forces 25

    • 4.1 Introduction 25
    • 4.2 Bargaining Power of Buyers 26
    • 4.3 Bargaining Power of Suppliers 26
      • 4.3.1 Threat from substitute 26
      • 4.3.2 Threat from a New Entrant 26
      • 4.3.3 Intensity of Competitive Rivalry 26

    5 Market Dynamics 28

    • 5.1 Drivers 28
      • 5.1.1 Smoking 28
      • 5.1.2 Environmental pollution 28
      • 5.1.3 Rising cases of infections 28
      • 5.1.4 Growing rates of early detection and awareness 28
      • 5.1.5 Rising rates of fast growing lung cancer 29
      • 5.1.6 Reimbursements and growing health insurance 29
    • 5.2 Restraints 29
      • 5.2.1 Poor efficacy, cure rates, and side effects of present treatment 29
      • 5.2.2 High failure rates of lung transplant surgeries 29
      • 5.2.3 High malignant nature and faster growth of lung cancer 29
      • 5.2.4 Poor life expectancy and quality of life of patients undergoing lung cancer treatment 30
      • 5.2.5 Loss of patents of lung cancer drugs 30
      • 5.2.6 Scarcity of lung organ and long waiting lines 30
    • 5.3 Opportunities 30
      • 5.3.1 Rising research and development 30
      • 5.3.2 Huge market 30
      • 5.3.3 Rising support from public and philanthropic bodies and increasing collaboration will help to drive down the development cost 30
      • 5.3.4 Targeted and genetic therapies 31
    • 5.4 Technological Trends and Advancements 31
      • 5.4.1 New targeted medicine works better and results with fewer adverse effects 31
      • 5.4.2 Impact of immunotherapy continues to grow in slowing advanced cancer growth 31
      • 5.4.3 New approaches in radiation therapy provide novel treatment options 32
      • 5.4.4 Advances in cancer treatment 32
      • 5.4.5 Availability of novel agents for NSCLC has increased the number of treated patients 33
    • 5.5 Challenges 33
      • 5.5.1 High bar for any new treatment 33
      • 5.5.2 The scarcity of lung transplant organs 33

    6 Global Lung Cancer Market, by Type 34

    • 6.1 SCLC 35
    • 6.2 NSCLC 36

    7 Global Lung Cancer Market, by Treatment 37

    • 7.1 Surgery 38
    • 7.2 Chemotherapy 39
    • 7.3 Radiotherapy 40
    • 7.4 Photodynamic Therapy (PDT) 41
    • 7.5 Laser Therapy 42

    8 Global Lung Cancer Market, by End-User 43

    • 8.1 Hospital & Clinics 44
    • 8.2 Cancer Research Centers 44
    • 8.3 Laboratories 45

    9 Global Lung Cancer Market, by Region 46

    • 9.1 North America 47
      • 9.1.1 U.S. 49
      • 9.1.2 Canada 51
    • 9.2 Europe 53
    • 9.3 Germany 56
      • 9.3.1 France 57
      • 9.3.2 Italy 59
      • 9.3.3 U.K. 60
      • 9.3.4 Spain 62
      • 9.3.5 Rest of Europe 63
    • 9.4 Asia Pacific 65
      • 9.4.1 China 68
      • 9.4.2 Japan 69
      • 9.4.3 India 71
      • 9.4.4 Republic of Korea 72
      • 9.4.5 Australia 74
      • 9.4.6 Rest of Asia Pacific 75
    • 9.5 Middle East & Africa 77
      • 9.5.1 UAE 79
      • 9.5.2 Saudi Arabia 81
      • 9.5.3 Egypt 82
      • 9.5.4 Rest of the Middle East & Africa 84

    10 Company Landscape 86

      11 Company Profiles 87

      • 11.1 F. Hoffmann-La Roche AG 87
        • 11.1.1 Overview 87
        • 11.1.2 Product/Business Segment Overview 87
        • 11.1.3 Financial Updates 88
        • 11.1.4 Key Developments 89
        • 11.1.5 SWOT Analysis 90
      • 11.2 Novartis 91
        • 11.2.1 Overview 91
        • 11.2.2 PRODUCT/BUSINESS SEGMENT OVERVIEW 91
        • 11.2.3 FINANCIAL UPDATES 92
        • 11.2.4 KEY DEVELOPMENTS 93
        • 11.2.5 SWOT ANALYSIS 94
      • 11.3 PFIZER INC. 95
        • 11.3.1 Overview 95
        • 11.3.2 PRODUCT/BUSINESS SEGMENT OVERVIEW 95
        • 11.3.3 FINANCIAL UPDATES 96
        • 11.3.4 KEY DEVELOPMENTS 97
        • 11.3.5 SWOT ANALYSIS 98
      • 11.4 Merck & Co., Inc. 99
        • 11.4.1 Overview 99
        • 11.4.2 Product Overview 99
        • 11.4.3 Financial Overview 100
        • 11.4.4 Key Developments 102
        • 11.4.5 SWOT ANALYSIS 103
      • 11.5 BRISTOL-MYERS SQUIBB 104
        • 11.5.1 Overview 104
        • 11.5.2 Product Portfolio 104
        • 11.5.3 Financial Overview 104
        • 11.5.4 KEY DEVELOPMENTS 106
        • 11.5.5 SWOT ANALYSIS 107
      • 11.6 Eli Lilly and Company 108
        • 11.6.1 Overview 108
        • 11.6.2 Product Overview 108
        • 11.6.3 Financial Overview 108
        • 11.6.4 KEY DEVELOPMENTS 110
        • 11.6.5 SWOT ANALYSIS 111
      • 11.7 Sanofi 112
        • 11.7.1 Company Overview 112
        • 11.7.2 Product/Business Segment Overview 112
        • 11.7.3 Financial Overview 113
        • 11.7.4 Key Development 114
        • 11.7.5 SWOT ANALYSIS 115

      Report You Might be Interested